- Home
- MQT vs GOSS Comparison
MQT vs GOSS Comparison
Compare MQT & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQT
- GOSS
- Stock Information
- Founded
- MQT 1992
- GOSS 2015
- Country
- MQT United States
- GOSS United States
- Employees
- MQT N/A
- GOSS N/A
- Industry
- MQT Investment Bankers/Brokers/Service
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- MQT Finance
- GOSS Health Care
- Exchange
- MQT Nasdaq
- GOSS Nasdaq
- Market Cap
- MQT 234.8M
- GOSS 212.9M
- IPO Year
- MQT N/A
- GOSS 2019
- Fundamental
- Price
- MQT $10.00
- GOSS $0.81
- Analyst Decision
- MQT
- GOSS Strong Buy
- Analyst Count
- MQT 0
- GOSS 5
- Target Price
- MQT N/A
- GOSS $9.20
- AVG Volume (30 Days)
- MQT 52.5K
- GOSS 2.3M
- Earning Date
- MQT 01-01-0001
- GOSS 11-07-2024
- Dividend Yield
- MQT 4.60%
- GOSS N/A
- EPS Growth
- MQT N/A
- GOSS N/A
- EPS
- MQT N/A
- GOSS N/A
- Revenue
- MQT N/A
- GOSS $105,322,000.00
- Revenue This Year
- MQT N/A
- GOSS N/A
- Revenue Next Year
- MQT N/A
- GOSS N/A
- P/E Ratio
- MQT N/A
- GOSS N/A
- Revenue Growth
- MQT N/A
- GOSS N/A
- 52 Week Low
- MQT $8.59
- GOSS $0.50
- 52 Week High
- MQT $10.67
- GOSS $1.60
- Technical
- Relative Strength Index (RSI)
- MQT 25.97
- GOSS 49.87
- Support Level
- MQT $10.45
- GOSS $0.76
- Resistance Level
- MQT $10.67
- GOSS $0.88
- Average True Range (ATR)
- MQT 0.12
- GOSS 0.08
- MACD
- MQT -0.06
- GOSS 0.01
- Stochastic Oscillator
- MQT 5.33
- GOSS 30.48
About MQT Blackrock MuniYield Quality Fund II Inc.
BLACKROCK MUNIYIELD QUALITY FUND II, INC. is a closed-end fund. Its objective is to provide shareholders with as high a level of current income exempt from federal income taxes as is consistent with its investment policies and prudent investment management. It invests in various sectors such as Transportation, Utilities, Health, County/City/Special District/School District, Education, Housing, Corporate, and Tobacco.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.